ORKA · Oruka Therapeutics, Inc.
$92.16
+0.28% last session
End-of-day data · updated 2026-07-28
Market cap
$5B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-36.2
Dividend yield
—
Beta
—
Avg volume
2M
Employees
0K
2D change
-2.13%
5D change
-1.90%
10D change
-2.70%
30D change
-0.44%
60D change
54.11%
MTD change
-3.31%
YTD change
197.59%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ORKA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-13
Latest call per bank · past 12 months
UBS
Buy$130
+41.1% vs priceBarclays
Overweight$160
+73.6% vs priceJefferies
Buy$45.00
-51.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | BTIG | Reiterates | Buy | $151 |
| 2026-07-01 | UBS | Maintains | Buy | $100 → $130 |
| 2026-06-23 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-05-18 | HC Wainwright & Co. | Reiterates | Buy | $120 |
| 2026-05-14 | BTIG | Reiterates | Buy | $151 |
| 2026-04-29 | HC Wainwright & Co. | Maintains | Buy | $75.00 → $120 |
| 2026-04-28 | UBS | Maintains | Buy | $75.00 → $100 |
| 2026-04-28 | Barclays | Maintains | Overweight | $78.00 → $160 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 20.1% above the 50-day MA ($75.30).
- Price vs 200-day MA: Trading 89.9% above the 200-day MA ($47.63).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.52) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($95.17).
ORKA Price Chart
Loading chart for ORKA…
Fundamentals
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.